Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Silence Therapeutics (SLN) over the last 7 years, with Dec 2024 value amounting to $336,000.

  • Silence Therapeutics' Depreciation & Amortization (CF) fell 5.81% to $81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $311,000, marking a year-over-year decrease of 31.14%. This contributed to the annual value of $336,000 for FY2024, which is 16.00% down from last year.
  • Per Silence Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $336,000 for FY2024, which was down 16.00% from $400,000 recorded in FY2023.
  • Over the past 5 years, Silence Therapeutics' Depreciation & Amortization (CF) peaked at $611,254 during FY2020, and registered a low of $336,000 during FY2024.
  • Over the past 3 years, Silence Therapeutics' median Depreciation & Amortization (CF) value was $400,000 (recorded in 2022), while the average stood at $378,667.
  • As far as peak fluctuations go, Silence Therapeutics' Depreciation & Amortization (CF) rose by 5.91% in 2020, and later fell by 29.26% in 2022.
  • Silence Therapeutics' Depreciation & Amortization (CF) (MRY) stood at $611,254 in 2020, then dropped by 7.49% to $565,486 in 2021, then dropped by 29.26% to $400,000 in 2022, then decreased by 0.00% to $400,000 in 2023, then decreased by 16.00% to $336,000 in 2024.
  • Its Depreciation & Amortization (CF) stands at $336,000 for FY2024, versus $400,000 for FY2023 and $400,000 for FY2022.